Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 8/20 | 0.36 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.34 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13654181 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL5042411 | 0.77 | ALDH1A1 (0.33) | ALDH1A1MAPTKDM4ETSHRKMT2A | |
| SCHEMBL6904874 | 0.77 | CA1 (0.32) | ALDH1A1 | |
| SCHEMBL9906779 | 0.76 | ALOX5AP (0.35) | ERN1 | |
| SCHEMBL6907417 | 0.75 | PREP (0.32) | ALDH1A1 | |
| SCHEMBL5139277 | 0.75 | ALDH1A1 (0.40) | ALDH1A1MAPTKDM4EPRKDCERN1 | |
| SCHEMBL5501219 | 0.74 | TDP1 (0.42) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL1534545 | 0.73 | ALDH1A1 (0.53) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL5696943 | 0.73 | ALDH1A1 (0.46) | ALDH1A1MAPTCYP1A2TSHRHTT | |
| SCHEMBL30286823 | 0.72 | MAPT (0.46) | ALDH1A1MAPTKDM4ECYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | ALDH1A1 553/4885MAPT 4379/4885KDM4E 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.